# Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer

> **NCT00225420** · PHASE1,PHASE2 · COMPLETED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 23 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** docetaxel
- **DRUG:** leuprolide acetate
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00225420
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2010-06
- **Final completion:** 2012-08
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2017-06-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00225420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00225420, "Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00225420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*